In a report released today, Danielle Brill from Raymond James maintained a Buy rating on PTC Therapeutics (PTCT). The company’s shares closed last Wednesday at $45.96, close to its 52-week low of $43.65.

According to, Brill is a 4-star analyst with an average return of 14.4% and a 50.3% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.

Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $66.75, which is a 44.6% upside from current levels. In a report issued on April 15, William Blair also maintained a Buy rating on the stock.

PTC Therapeutics’ market cap is currently $3.26B and has a P/E ratio of -7.10. The company has a Price to Book ratio of -10.59.

Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.